Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, PhD, Anne Kisielewski, BS, Ezio Bonvini, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 1387.

https://doi.org/10.1182/blood-2019-126791

Published: 2019

Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2019) 134 (Supplement_1): 1410.

https://doi.org/10.1182/blood-2019-128485

Published: 2019

Journal Articles

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

John Godwin, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2018) 132 (Supplement 1): 4065.

https://doi.org/10.1182/blood-2018-99-118522

Published: 2018

Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD

Blood (2018) 132 (Supplement 1): 444.

https://doi.org/10.1182/blood-2018-99-111539

Published: 2018

Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Blood (2018) 132 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2018-99-112615

Published: 2018

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

Journal Articles

Clonal Expansion and Long-Term Persistence of Rhesus Macaque NK Cells with an Adaptive Phenotype

Chuanfeng Wu, MDPhD, Diego A Espinoza, Samson J. Koelle, BA, Di Yang, MD, Heinrich Schlums, Jan K. Davidson-Moncada, MD PhD, Rong Lu, Amitinder Kaur, Hammer Quirin, Brian Li, Sandhya R. Panch, MD MPH, Robert E Donahue, Richard W. Childs, Chiara Romagnani, Yenan Bryceson, Cynthia E. Dunbar, MD

Blood (2016) 128 (22): 549.

https://doi.org/10.1182/blood.V128.22.549.549

Published: 2016

Journal Articles

Identification and Ex Vivo Expansion of a Circulating NK Cell Progenitor Population That Leads to Sustained Production of CD56+ NK Cells

Jan K. Davidson-Moncada, MD PhD, Taylor Harrison Wand, BA, Robert N. Reger, B.S., Chuanfeng Wu, PhD, Cynthia E. Dunbar, MD, Richard W. Childs, MD

Blood (2015) 126 (23): 850.

https://doi.org/10.1182/blood.V126.23.850.850

Published: 2015

Journal Articles

Specific Impaired CD56+ NK Cell Development in GATA2 Deficiency As Revealed By Ex Vivo NK Expansion

Moonjung Jung, MD, Jan K. Davidson-Moncada, MD PhD, Chuanfeng Wu, PhD, Samson Koelle, BA, Thomas Winkler, MD, Danielle M. Townsley, MD, Amy Hsu, BS, Keyvan Keyvanfar, BS, Steven M. Holland, MD, Dennis D. Hickstein, MD, Richard W. Childs, MD, Cynthia E. Dunbar, MD

Blood (2014) 124 (21): 1419.

https://doi.org/10.1182/blood.V124.21.1419.1419

Published: 2014

Journal Articles

The Unique Ontogeny Of Natural Killer Cells As Revealed By Genetic Barcoding In The Nonhuman Primate Model

Chuanfeng Wu, PhD, Jan K. Davidson-Moncada, MD, PhD, Rong Lu, PhD, Brian Li, Allen E. Krouse, Mark E. Metzger, Robert E. Donahue, Irving L. Weissman, MD, Richard Childs, MD, Cynthia E. Dunbar, MD

Blood (2013) 122 (21): 15.

https://doi.org/10.1182/blood.V122.21.15.15

Published: 2013

Journal Articles

Rhesus Macaque NK Cells Expanded Ex Vivo Undergo Similar Phenotypic and Functional Changes Observed With Expanded Human NK Cells Providing An Excellent Model To Optimize Adoptive NK Cell Transfer

Jan K. Davidson-Moncada, MD, PhD, Richard Childs, MD, Cynthia E. Dunbar, MD, Robert Reger, Ritesh Kotecha, Maria Berg, Chuanfeng Wu, PhD

Blood (2013) 122 (21): 2028.

https://doi.org/10.1182/blood.V122.21.2028.2028

Published: 2013

Journal Articles

MicroRNA-155 Modulates Transforming Growth Factor-β Signaling In Chronic Lymphocytic Leukemia through Targeting of Casein Kinase γ Isoform 2

Jan K. Davidson-Moncada, MD, PhD, Taotao Zhang, MD, PhD, Piali Mukherjee, PhD, Paul Hakimpour, MSc, Richard R. Furman, MD, Nina Papavasiliou, PhD, Wayne Tam, MD, PhD

Blood (2010) 116 (21): 3584.

https://doi.org/10.1182/blood.V116.21.3584.3584

Published: 2010

NARROW

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clonal Expansion and Long-Term Persistence of Rhesus Macaque NK Cells with an Adaptive Phenotype

Identification and Ex Vivo Expansion of a Circulating NK Cell Progenitor Population That Leads to Sustained Production of CD56+ NK Cells

Specific Impaired CD56+ NK Cell Development in GATA2 Deficiency As Revealed By Ex Vivo NK Expansion

The Unique Ontogeny Of Natural Killer Cells As Revealed By Genetic Barcoding In The Nonhuman Primate Model

Rhesus Macaque NK Cells Expanded Ex Vivo Undergo Similar Phenotypic and Functional Changes Observed With Expanded Human NK Cells Providing An Excellent Model To Optimize Adoptive NK Cell Transfer

MicroRNA-155 Modulates Transforming Growth Factor-β Signaling In Chronic Lymphocytic Leukemia through Targeting of Casein Kinase γ Isoform 2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only